Pharmaron Beijing (300759.SZ) intends to issue new H shares through general authorization for private placement.

Pharmaron Beijing (300759.SZ) announcement, the company plans to issue new overseas listed foreign capital shares (H shares) according to the authorization granted by the shareholders' meeting to the board of directors under the "Proposal on Authorization for the Shareholders' Meeting to Grant the Board of Directors the General Authority to Issue Additional H Shares of the Company" approved at the 2024 annual shareholders' meeting. On January 14, 2026 (after trading hours), the company signed a placement agreement with Goldman Sachs (Asia) LLC and HSBC Bank (Hong Kong). According to the placement agreement, the company agrees to appoint placement agents and the placement agents individually and not jointly agree to act as the company's agents, and use their best efforts to solicit several placement subscribers to subscribe to 58,440,762 million new H shares to be issued by the company at a price of HK$22.82 per share under the general issuance authorization.